CC2i Genomics has introduced its minimal residual disease (MRD) test, C2inform, to bring cancer monitoring to centres in Europe.
The latest move comes after the company secured CE-IVD marking for the test in the EU and UK.
The company will make the software-as-a-medical-device MRD test available in countries that accept the CE Mark.
C2inform provides a streamlined process for in-house use by any genomic cancer lab or pathology lab to offer patient testing.
